Teva’s Latest Pharmacokinetic Modeling Data Shows UZEDY® Benefits for Schizophrenia Patients at SIRS 2024

Teva Pharmaceuticals Unveils Promising PK Modeling Data and Clinical Insights at SIRS 2024

At the Schizophrenia International Research Society (SIRS) 2024 Congress, Teva Pharmaceuticals, a leading U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has revealed significant findings from its LAI schizophrenia research program. This includes crucial data evaluating UZEDY®, an extended-release injectable suspension of risperidone designed for subcutaneous use every one or two months in adults with schizophrenia.

Key highlights from the presented studies include:

  1. Pharmacokinetic (PK) modeling insights shedding light on potential dosing conversion strategies for transitioning patients from a long-acting injectable (LAI) formulation of risperidone microspheres (R064766) to UZEDY®.
  2. New analysis from the Phase 3 RISE trial, further affirming the efficacy and safety profile of UZEDY® in adults with schizophrenia.
  3. The ADVANCE global survey study, offering real-world perspectives on LAI utilization from healthcare professionals, caregivers, and patients.

Dr. Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer at Teva, emphasized the significance of these findings in advancing treatment innovation for schizophrenia patients. He noted that schizophrenia treatment needs and preferences evolve over time, and the data collectively underscored the efficacy and safety of UZEDY®, potentially aiding in reducing relapse and hospitalization rates.

The PopPK modeling analysis focused on devising optimal strategies for switching patients to UZEDY® from different LAI formulations. Simulations indicated that switching to UZEDY® at 4-6 weeks after the last dose of R064766 provided comparable PK exposures by the second dose. The analysis aims to address the current knowledge gap on optimal switching strategies between various LAI options with differing PK properties.

Other key data presented at SIRS 2024 included:

  • Further insights from the RISE trial, including estimations of number needed to treat (NNT) and number needed to harm (NNH), aiding healthcare providers in understanding the benefits and risks of UZEDY®.
  • Qualitative findings from the ADVANCE surveys, highlighting regional differences in LAI utilization rates and addressing challenges related to patient acceptance and adherence.

The comprehensive data presented by Teva at SIRS 2024 underscores its commitment to advancing schizophrenia treatment and improving patient outcomes.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter